Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSATargeted Therapy in Patients with Suspected MRSA Pneumonia

Abstract

The objective of this study was to evaluate the impact of pharmacistordered methicillin-resistant Staphylococcus aureus (MRSA) PCR testing on the duration of empirical MRSA-Targeted antibiotic therapy in patients with suspected pneumonia. This is a retrospective analysis of patients who received vancomycin or linezolid for suspected pneumonia before and after the implementation of a pharmacist-driven protocol for nasal MRSA PCR testing. Patients were included if they were adults of +18 years of age and initiated on vancomycin or linezolid for suspected MRSA pneumonia. The primary endpoint was the duration of vancomycin or linezolid therapy. After screening 368 patients, 57 patients met inclusion criteria (27 pre-PCR and 30 post-PCR). Baseline characteristics were similar between the two groups, with the majority of patients classified as having health care-Associated pneumonia (68.4%). The use of the nasal MRSA PCR test reduced the mean duration of MRSA-Targeted therapy by 46.6 h (74.0 + 48.9 h versus 27.4 + 18.7 h; 95% confidence interval [CI], 27.3 to 65.8 h; P + 0.0001). Fewer patients in the post-PCR group required vancomycin serum levels and dose adjustment (48.1% versus 16.7%; P+ 0.02). There were no significant differences between the pre-And post-PCR groups regarding days to clinical improvement (1.78 + 2.52 versus 2.27 + 3.34; P + 0.54), length of hospital stay (11.04 + 9.5 versus 8.2 + 7.8; P + 0.22), or hospital mortality (14.8% versus 6.7%; P + 0.41). The use of nasal MRSA PCR testing in patients with suspected MRSA pneumonia reduced the duration of empirical MRSA-Targeted therapy by approximately 2 days without increasing adverse clinical outcomes.